GlassScriptPhysician profile
Barry P Kaufman
NPI 1154499085
$156,800.11
in general payments reported to CMS, 2019-2025
48 companies · $2,575 in 2025
The $2,575 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62K · 2020: $6,416 · 2021: $16K · 2022: $37K · 2023: $27K · 2024: $5,167 · 2025: $2,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Travel and Lodging: $6,258 · Food and Beverage: $4,239 · Consulting Fee: $1,800 · Education: $32.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,024.50 |
| Travel and Lodging | $6,258.36 |
| Food and Beverage | $4,238.80 |
| Consulting Fee | $1,800.00 |
| Education | $32.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $38,661.35 | 2019-2025 | |
| Pfizer INC. | $36,407.54 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $34,188.35 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $33,093.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $4,428.46 | 2019-2025 | Entyvio |
| Celgene Corporation | $4,320.14 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $1,002.05 | 2019-2025 | Livdelzi |
| Janssen Biotech, INC. | $931.88 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $815.79 | 2019-2024 | Xifaxan |
| Qol Medical, LLC | $464.30 | 2019-2024 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $329.96 | 2019-2024 | Dificid |
| Daiichi Sankyo INC. | $309.30 | 2019-2023 | Injectafer |
| Nestle Healthcare Nutrition INC. | $250.60 | 2020-2023 | |
| Regeneron Healthcare Solutions, INC. | $174.75 | 2022-2024 | Dupixent |
| Shionogi INC | $161.14 | 2019-2020 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $117.90 | 2024 | Omvoh, Zepbound |
| Aimmune Therapeutics, INC. | $105.59 | 2024-2025 | Zenpep |
| Ferring Pharmaceuticals INC. | $100.04 | 2021-2023 | Rebyota |
| Ardelyx, INC. | $92.96 | 2023-2025 | Ibsrela |
| Redhill Biopharma INC. | $83.97 | 2021-2023 | Aemcolo, Talicia |
| Alfasigma USA, INC. | $72.94 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $62.89 | 2019 | |
| Genzyme Corporation | $58.30 | 2023-2024 | |
| Ucb, INC. | $53.81 | 2019-2020 | |
| Intercept Pharmaceuticals, INC. | $49.06 | 2019-2024 | |
| Boston Scientific Corporation | $47.29 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $45.47 | 2024 | Iqirvo |
| Evoke Pharma, INC. | $42.69 | 2020-2023 | Gimoti |
| Allergan, INC. | $34.23 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $30.03 | 2020-2021 | |
| Dova Pharmaceuticals | $28.25 | 2019 | |
| Romark Laboratories, Lc | $27.42 | 2020 | |
| Organon LLC | $26.76 | 2023 | Renflexis |
| Phathom Pharmaceuticals, INC. | $22.99 | 2024 | Voquezna |
| Ambu INC. | $21.93 | 2021 | |
| W. L. Gore & Associates, INC. | $19.01 | 2023 | Gore Cardioform Septal Occluder |
| Celltrion USA INC. | $18.71 | 2025 | Vegzelma |
| Pharmacosmos Therapeutics INC. | $16.74 | 2023 | Monoferric |
| Amag Pharmaceuticals, INC. | $15.57 | 2021 | |
| Intra-Sana Laboratories | $14.69 | 2025 | Glycate, Reltone 400 Mg, Reltone 200 Mg |
| Novo Nordisk INC | $14.00 | 2021 | |
| Horizon Therapeutics Plc | $13.12 | 2020 | |
| Ironwood Pharmaceuticals, INC | $12.20 | 2020 | |
| Echosens North America, INC. | $12.03 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.